Acalabrutinib May Offer a New Therapeutic Approach for Consolidation and Maintenance of Primary CNS Lymphoma with Expression of MYD88 and CD79B Gene Variants: A Case Report and Literature Review of Primary CNS Lymphoma in the BTKi Era

We present the case of a patient with Primary CNS Lymphoma (PCNSL), with MYD88 and CD79B gene variants, that was unable to complete standard induction and consolidation treatment due to toxicity and co-morbidities after 3 cycles of MATRix. Though he had responded to truncated induction, acalabrutinib, the BTK inhibitor, was used in an attempt to consolidate and maintain his response. He has an ongoing remission at 18 months of follow up. Following the case presentation, we provide a review on PCNSL, the evolution of therapy, and how BTK inhibitors are now emerging treatments being incorporated into salvage of relapsed and refractory disease and first-line treatment in some clinical trial. This is the first reported case report in the literature of acalabrutinib use for consolidation and maintenance of PCNSL. We hope this can support clinical trial design for BTKi use in this setting in the future.